Actinium In Research Collaboration with Columbia University to Study Actimab-A in AML

 Collaboration builds on the groundbreaking research of Columbia University oncologist Dr. Siddhartha Mukherjee that uses gene-editing to remove the CD33 surface protein from hematopoietic stem cells

- Actimab-A to be used post-transplant of these engineered stem cells to prevent relapse by selectively targeting residual CD33 positive leukemia cells while sparing the engineered stem cells

- High rates of measurable residual disease negativity demonstrated by Actimab-A + CLAG-M validates merits of Actimab-A's use to prevent disease relapse post gene edited stem cell transplant

- Actimab-A + CLAG-M data to be presented in oral presentation at American Society of Hematology Annual Meeting on Saturday, December 10^th highlighting 53% 1-year and 32% 2-year overall survival, 67% Overall Response Rate and 72% MRD negativity in patients with relapsed or refractory acute myeloid leukemia

https://www.biospace.com/article/releases/actinium-pharmaceuticals-inc-announces-research-collaboration-with-columbia-university-to-study-actimab-a-in-aml-patients-following-transplant-of-engineered-hematopoietic-stem-cells-gene-edited-to-be-cd33-negative/